Moonwalk Biosciences raises $70M to move RNAi obesity drug MW101 toward first-in-human trials in 2027
read at BioSpace ↗DealPositive
Moonwalk Biosciences, an obesity drug developer backed by Eli Lilly, announced a $70 million Series B financing.
The funding will support its lead RNAi candidate, MW101, which in mouse studies produced weight loss and reduced fat while preserving muscle mass, without decreasing food intake.
The company plans to begin first‑in‑human trials in late 2027. The round was led by Alpha Wave Ventures and YK Bioventures, with participation from Lilly and Gaorong V.
source
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic”
read at BioSpace ↗525 words · retrieved Sep 8
comments(0)
5-min edit window · permanent after that